Form 4: Foundation Fighting Blindness Reports Conversion of Preferred Stock in Opus Genetics

Foundation Fighting Blindness reports the conversion of Series A non-voting convertible preferred stock into common stock of Opus Genetics following stockholder approval.

Summary

• Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. reported transactions related to Opus Genetics, Inc.
• The transactions involved the conversion of Series A non-voting convertible preferred stock into common stock.
• 6,927,419 shares of preferred stock were converted into common stock on May 5, 2025.
• The conversion was triggered by stockholder approval on April 30, 2025.
• Foundation Fighting Blindness, Inc. is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund and may be deemed to beneficially own the securities owned directly by RDF.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to a stock conversion, which is generally a neutral event. The conversion suggests the company is progressing as planned, hence a slightly positive sentiment.

Industry Context

This filing reflects a corporate action related to the capital structure of Opus Genetics, a company in the biotechnology sector. Conversions of preferred stock to common stock are a fairly common event, especially after key milestones are achieved.

Key Dates

Keywords

Opus Genetics, Foundation Fighting Blindness, stock conversion, preferred stock, common stock, beneficial ownership, Form 4